CHAPTER 9 Delivering HPV vaccine in the industrial and developing world: the role of the ob-gyn community

International Journal of Gynecology and Obstetrics

Volumn 94, Issue SUPPL. 1, 2006, Pages

  Kane, Mark A ^a  

^a NONE

Author keywords

Developing world; HPV vaccine; Immunization

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; CAUSE OF DEATH; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DIAGNOSTIC VALUE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; PRIORITY JOURNAL; UTERINE CERVIX CANCER; VACCINATION; WART VIRUS;

EID: 33846602615     PISSN: 00207292     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0020-7292(07)60015-0     Document Type: Article

References (18)

1. Mao C., Koutsky L., Ault K., Wheeler C., Brown D., Wiley D., et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 107 1 (2006) 18-27
2. Villa L., Costa R., Petta C., Andrade R., Ault K., Giuliano A., et al. Prophylactic quadrivalent human papillo-mavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6 5 (2005) 271-278
3. Margolis H., Alter M., and Hadler S. Hepatitis B: evolving epidemiology and implications for control. Semin Liver Dis 11 2 (1991) 84-92
4. Centers for Disease Control and Prevention (CDC). Progress in reducing global measles deaths, 1999-2004. MMWRMorb Mortal Wkly Rep 55 9 (2006 Mar 10) 247-249
5. Centers for Disease Control and Prevention (CDC). Progress toward interruption of wild poliovirus transmission-worldwide, January 2004-March 2005. MMWR Morb Mortal Wkly Rep 54 16 (2005 Apr 29) 408-412
6. World Health Organization. World Health Report 2005. Statistical Annex No. 7
7. Kane M., and Brooks A. New immunization initiatives and progress toward the global control of hepatitis B. Curr Opin Infect Dis 15 5 (2002) 465-469
8. World Health Organization. Available at: http://www.who.int/immunization_monitoring/diseases/hepatitis/en/index.html
9. Kaddar M., Lydon P., and Levine R. Financial challenges of im-munization: a look at GAVI. Bull World Health Organ 82 9 (2004) 697-702
10. Manhart L., Holmes K., Koutsky L., Wood T., Kenney D., Feng Q., et al. Human papillomavirus infection among sexually active young women in the United States: implications for developing a vaccination strategy. Sex Transm Dis Mar 27 (2006) (Epub, ahead of publication).
11. Averhoff F., Williams W., and Hadler S. Immunization of adolescents. Am Fam Physician 55 1 (1997) 159-167
12. Vandelaer J., Birmingham M., Gasse F., Kurian M., Shaw C., and Gamier S. Tetanus in developing countries: an update on the Maternal and Neonatal Tetanus Elimination Initiative. Vaccine 21 24 (2003) 3442-3445
13. Partridge J., and Koutsky L. Genital human papillomavirus infection in men. Lancet Infect Dis 6 1 (2006) 21-31
14. Mahoney F., and Kane M. Hepatitis B vaccine. In: Plotkin S., and Orenstein W. (Eds). Vaccine. 3rd ed. (1999), W.B. Saunders, Philadelphia, Pa, USA 158-182
15. Poland G., and Jacobson R. Understanding those who do not understand: a brief review of the anti-vaccine movement. Vaccine 19 (2001) 2440-2445
16. Francois G., Duclos P., Margolis H., Lavanchy D., Siegrist C., Meheus A., et al. Vaccine safety controversies and the future of vaccination programs. Pediatr Infect Dis J 24 11 (2005) 953-961
17. Aylward R., and Heymann D. Can we capitalize on the virtues of vaccines? Insights from the polio eradication initiative. Am J Public Health 95 5 (2005) 773-777
18. World Health Organization. WHO consultation on human papillomavirus vaccines. Wkly Epidemiol Rec 80 35 (2005) 299-302